Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (TLX): 6 pipeline candidates · 4 upcoming catalysts · ~34 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
34.4 months
D/E 1.80 · 0% dilution
Lead: Approved
6 candidates
4 upcoming, next in ~136d
2 buys · 0 sells (180d)
A transparent, data-derived signal for Telix Pharmaceuticals Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.4B
Cash
$141.9M
Quarterly Burn
$17.3M
Runway
34.4 mo
Revenue
$803.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| 153sm-dotmp | Phase 1 |
| 177lu-tlx591 | Phase 3 |
| 68ga-psma-11 | Phase 3 |
| abiraterone | Phase 3 |
| illuccix | Approved |
| ipa | Phase 3 |
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$14.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 564,757 | $5.4M |
| lazard asset management llc | 289,917 | $2.8M |
| portland investment counsel inc. | 266,200 | $2.5M |
| morgan stanley | 116,440 | $1.1M |
| schonfeld strategic advisors llc | 34,873 | $334K |
| vanguard personalized indexing management, llc | 33,253 | $318K |
| ubs group ag | 32,300 | $309K |
| xtx topco ltd | 26,007 | $249K |
| iht wealth management, llc | 25,035 | $240K |
| vident advisory, llc | 16,653 | $159K |
Showing top 10 of 32 institutional holders of Telix Pharmaceuticals Limited. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Telix Pharmaceuticals Limited's pipeline?
Telix Pharmaceuticals Limited (TLX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Telix Pharmaceuticals Limited's lead drug candidate?
Telix Pharmaceuticals Limited's most advanced tracked candidate is 153sm-dotmp (Phase 1) for Bone Pain.
What is Telix Pharmaceuticals Limited's next catalyst?
Telix Pharmaceuticals Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific " — expected November 1, 2026.
What is Telix Pharmaceuticals Limited's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Telix Pharmaceuticals Limited has approximately 34.4 months of cash runway.
What is Telix Pharmaceuticals Limited's market capitalization?
Telix Pharmaceuticals Limited's market capitalization is approximately $3.4B.
Get the full picture on Telix Pharmaceuticals Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.